Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'Ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti-Foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Soria A, et al. Among authors: schiavini m. Liver Int. 2020 Apr;40(4):769-777. doi: 10.1111/liv.14386. Epub 2020 Feb 3. Liver Int. 2020. PMID: 31970845
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
D'Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-Foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia Study Group. D'Ambrosio R, et al. Among authors: schiavini m. J Hepatol. 2019 Mar;70(3):379-387. doi: 10.1016/j.jhep.2018.11.011. Epub 2018 Nov 23. J Hepatol. 2019. PMID: 30472321
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. Fabbiani M, et al. Among authors: schiavini m. J Viral Hepat. 2021 Mar;28(3):558-568. doi: 10.1111/jvh.13454. Epub 2021 Jan 2. J Viral Hepat. 2021. PMID: 33306247
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study.
Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Aghemo A, et al. Among authors: schiavini m. Dig Liver Dis. 2021 May;53(5):612-619. doi: 10.1016/j.dld.2020.08.007. Epub 2020 Sep 8. Dig Liver Dis. 2021. PMID: 32917546
Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
Passerini M, Schiavini M, Magni CF, Landonio S, Niero F, Passerini S, Croci AL, Bolis M, Scalzi V, Gubertini G, Ricci ED, Galli M, Rizzardini G. Passerini M, et al. Among authors: schiavini m. Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1208-1215. doi: 10.1097/MEG.0000000000001239. Eur J Gastroenterol Hepatol. 2018. PMID: 30138160
Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.
Angeli E, Mainini A, Cargnel A, Uberti-Foppa C, Orani A, Carbone R, Andreoni M, Schiavini M, Giorgi R, Rizzardini G, Gubertini G; ICoS-2 Group. Angeli E, et al. Among authors: schiavini m. Curr HIV Res. 2009 Jul;7(4):447-55. doi: 10.2174/157016209788680507. Curr HIV Res. 2009. PMID: 19601782 Clinical Trial.
37 results